Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Clarification regarding Intervacc’s vaccine Strangvac
Stockholm, December 17, 2021 – Due to the large and volatile trading in the company’s share based on speculations on social media, Intervacc wants to clarify that Strangvac is centrally approved by EMA for sales throughout the EU and that sales will start...Intervacc comments on the trading halt of the company’s share on Nasdaq First North
Stockholm, December 15, 2021 – Nasdaq Stockholm has decided to temporarily stop trading in Intervacc after a volatile trading session and a decline in the share price. The reason for the price decline is speculation in social media about the company’s...Sales launch of Intervacc vaccine against equine Strangles during Q1 2022
Stockholm, December 14, 2021 – Intervacc AB (“Intervacc”) announces today that sales of the company’s Strangles vaccine Strangvac are planned to begin in the first quarter of 2022. Intervacc’s vaccine against equine Strangles, a widespread and common...Nomination Committee appointed in respect of AGM 2022 in Intervacc
Stockholm, November 30, 2021 – According to the principles for the appointment of the Nomination Committee in Intervacc AB (publ) adopted at the annual general meeting held on June 9th, 2021, the Nomination Committee for the annual general meeting 2022 shall be...Interim report January – September 2021
The period in summary Third quarter July 1 – September 30, 2021 On August 16th the European Commission granted a Marketing Authorisation for Strangvac within the European Union. The Veterinary Medicines Directorate (VMD) of the United Kingdom granted a Marketing...Nyhetstjänster
